

Unveiling the Data: Post-Complete Response Letter Scientific Meeting Requests under GDUFA III

Generic Drugs Forum (GDF) 2024:
Regulatory Considerations to Enhance Generic Drug Access
CDER Small Business & Industry Assistance (SBIA)
April 10, 2024

Hiren H. Patel, Ph.D.

Senior Staff Fellow, Division of Bioequivalence II
Office of Bioequivalence, Office of Generic Drugs
CDER | U.S. FDA

Disclaimer



This presentation reflects the views of the author and should not be construed to represent FDA's views or policies.



Learning Objectives



- ✓ An overview of post-complete response letter (CRL) scientific meeting requests (MRs) under GDUFA III
- ✓ Summary of the historical information
- ✓ Case studies on the effectiveness of post-CRL scientific MRs



Post-CRL Scientific Meetings

- **Purpose:** To provide an applicant with scientific advice on possible approaches to address deficiencies identified in a CRL related to establishing equivalence
- **Criteria:**
 - Complex product or in FDA's judgment, the request raises issues that are best addressed via this meeting process
 - Include one or more of the following for discussion as it relates to establishing equivalence
 - A. A new equivalence study needed to address the deficiencies identified in the CRL
 - B. An approach that is different from that submitted in the ANDA
 - C. A new comparative use human factors study
 - D. A new approach to demonstrate sameness of a complex active pharmaceutical ingredient


Likely Deny Scenario

- In FDA's judgment, questions that can be more adequately addressed through controlled correspondence
- Incomplete meeting package
 - Ideally, the complete meeting package includes but not limited to
 - List of questions and their relevant criteria, per GDUFA III commitment letter, with supporting rationale or data, as applicable
 - Supporting information about the drug product (e.g., complex vs. non-complex)



Additional Remarks...


- Applicants are eligible to request a post-CRL scientific meeting even if
 - There was no prior product development meeting for respective ANDA
 - They already submitted a post-CRL clarification teleconference to seek clarification concerning deficiencies identified in a CRL
- If an applicant has additional questions after a post-CRL scientific meeting, they may submit a controlled correspondence (preferred) or request another post-CRL scientific meeting (based on eligibility)
 - Same question(s) should not be asked through multiple avenues



General Timeline




ANDAs in “Complete Response” status that meet eligibility requirements



Post-CRL Scientific MRs: Synopsis



- 25 Post-CRL scientific MRs has been received between Oct. 2022 and Jan. 2024
- 20 MRs were for complex products, and 5 MRs were for non-complex products
- 17 MRs were granted, and 8 MRs were denied



Utilization of MRs

- MRs included wide range of dosage forms with different routes of administration for generic drug products

No. of Post CRL Scientific MRs by Route of Administration/Dosage Forms



Post-CRL Scientific MRs: A Closer Look



Category	Granted Meetings		Denied Meetings
No. of MRs	17		8
Type of Drug Products	16 Complex products 1 Non-complex product		5 Complex products 3 Non-complex products
Basis/ Criteria	Criteria A: 5 MRs Criteria B: 7 MRs Criteria D: 2 MRs	<ul style="list-style-type: none"> • Alternative approach • Complex issues • Non-complex product met one of the criteria • Inter-office collaboration is needed 	<ul style="list-style-type: none"> • Outside the scope • Appropriate for controlled correspondence • Same question(s) at multiple avenues

A: A new equivalence study needed to address the deficiencies identified in the CRL

B: An approach that is different from that submitted in the ANDA

D: A new approach to demonstrate sameness of a complex active ingredient



Note: Some of the MRs were qualified under more than one criteria

Post-CRL Scientific MRs: Distribution



➤ Format of granted MRs

➤ Lead Offices of granted MRs



Lead Offices are the ones who chaired the post-CRL meetings when granted. However, different offices were collaborated across disciplines to address the questions as applicable.

OB: Office of Bioequivalence
OPQ: Office of Pharmaceutical Quality
OSCE: Office of Safety and Clinical Evaluation



Case Studies: Granted MRs

- **Category:** Complex product + a new equivalence study was needed
- ☐ Example 1: Metered Aerosol Inhalation Product
 - Inadequacy about Realistic Aerodynamic Particle Size Distribution (rAPSD) and computational fluid dynamics (CFD) modeling study
 - The applicant proposed a detailed study design to address the deficiencies identified in the CRL
- ☐ Example 2: Intravenous Injectable Product
 - Recommendations to conduct a new pivotal in-vitro particle size distribution (PSD) study using adequate exhibit batches
 - The applicant sought the feedback on the proposal of manufacturing three batches of test product at commercial scale and utilize modified approach to support bioequivalence (BE), compared to the product-specific guidance (PSG) recommendations

Case Studies: Granted MRs

Continued..

The logo for the U.S. Food and Drug Administration (FDA), consisting of the letters "FDA" in white on a blue square background.

- **Category:** Complex product + a different approach from the submission in ANDA
- ❑ Example 3: Topical Aerosol/Foam Product
 - Recommendations to conduct in-vivo BE study with clinical endpoints, per the PSG
 - The applicant proposed to pursue in-vitro characterization-based BE approach
- ❑ Example 4: Topical Lotion Product
 - Recommendations to conduct one of the in-vitro bioequivalence study [i.e., in-vitro permeation test (IVPT)] under characterization-based BE approach
 - The applicant proposed physiologically based pharmacokinetic (PBPK) modeling approach

Case Studies: Granted MRs

Continued..

The logo for the U.S. Food and Drug Administration (FDA), consisting of the letters "FDA" in white on a blue square background.

- **Category:** Complex Product + a new equivalence study was needed + a different approach from the submission in ANDA

- **Example 5: Metered Aerosol Inhalation Products**
 - Same drug product with two different strengths submitted in two different ANDAs from the same applicant
 - Similar deficiencies were communicated for both applications due to similar scientific issues
 - The applicant sought clarification and concurrence for a series of repeated/new equivalence studies to address deficiencies identified in the CRLs for respective ANDAs
 - To ensure efficiency, a two-hours combined meeting was granted to discuss both applications

Case Studies: Granted MRs

Continued..

The logo for the U.S. Food and Drug Administration (FDA), consisting of the letters "FDA" in white on a blue square background.

- **Category:** Complex product + an alternative approach
- ❑ Example 6: Intravenous Injectable Product
 - The applicant proposed an alternate approach for statistical evaluation of the pharmacokinetic BE study to address the deficiency in the CRL
- **Category:** Non-complex product + an alternative approach
- ❑ Example 7: Oral Extended-Release Tablets
 - The applicant proposed an alternative approach (i.e., utilization of population pharmacokinetic approach) to address the deficiency comments related to T_{lag} , observed in the submitted data

Case Studies: Granted MRs

Continued..

The logo for the U.S. Food and Drug Administration (FDA), consisting of the letters "FDA" in white on a blue square background.

- **Category:** Non-complex product + complex issues
- Example 8: Oral Immediate-Release Tablets
 - The applicant sought the Agency's input for utilization of the alternative study design compared to the recommendations in the general guidance for Biopharmaceutics Classification System-Based Biowaivers and relevant challenges (e.g., Complexity and instability of active ingredient in acidic media)

Common Observations for Denial of MRs

- Non-complex products and outside the scope of a post CRL scientific MR
- More than one meeting requested to discuss a particular issue(s) or question(s) at different avenues
- Question is more appropriate to be addressed through Controlled Correspondence
- Disputes regarding the relevance of deficiency comment(s)
- Request to evaluate/re-consider the data



Take Home Message

- The purpose of post-CRL scientific MRs is to provide scientific advice on possible approaches to address communicated deficiencies in a CRL related to establishing equivalence
- FDA will not pre-review any specific scientific data submitted in the meeting package within the scope of post-CRL scientific MR
 - However, it is encouraged to provide supporting data for the proposed approach, as applicable
- In general, the acceptability of any proposed new approach along with study data is assessed upon submission of an ANDA amendment with relevant data and information



Challenge Question #1



- If an applicant has additional questions after a post-CRL scientific meeting, the applicant may request a subsequent post-CRL scientific meeting or submit a controlled correspondence.
 - A. True
 - B. False



Challenge Question #2



- Since the applicant did not have product development meeting, the application is not qualified for post-CRL scientific meeting request, despite it is a complex product and meet one of the four criteria outlined in the GDUFA III commitment letter.
 - A. True
 - B. False

Resources to Refer...

- [GDUFA Commitment Letter](#)
- [Draft Guidance for Industry: Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA](#)



Acknowledgements

- Anil K. Nair, PhD
- Diana Vivian, PhD
- Xiaojian Jiang, PhD
- Hongling Zhang, PhD
- Tao Bai, PhD
- Partha Roy, PhD
- Bioequivalence Assessors



Thank
you

The words "Thank you" are written in a vibrant orange, cursive script. The text is set against a white, rounded rectangular background that has a subtle drop shadow and a slight 3D effect, making it look like a sticker or a piece of paper with a curled edge on the left side.

Questions?

Hiren H. Patel, Ph.D.

Senior Staff Fellow, Division of Bioequivalence II
Office of Bioequivalence, Office of Generic Drugs
CDER | U.S. FDA



U.S. FOOD & DRUG
ADMINISTRATION